ASH News Daily 2012 - Saturday, December 8, 2012 - (Page B-10)

Page B–10 ® ASH NewS DAily Saturday, December 8, 2012 Minority Graduate Student Abstract Achievement Award Recipients he Minority Graduate Student Abstract Achievement Award is part of the ASH Abstract Achievement Award program and is meant to encourage minority graduate students in the field of hematology. It is part of the T Don’t Miss the Special Symposium on Epigenetics in Hematopoiesis his exciting session on one of the hottest topics in hematology will focus on the epigenetic paradigms that control gene expression across the hematopoietic cell lineages, the molecular mechanisms by which epigenetic alterations control hematopoietic stem cell function and differentiation, and the effects of gene mutations in hematopoietic malignancies. It will be offered today only. It is scheduled from 4:00 to 5:30 p.m., in Room A103 of the convention center. Chair: Ari Melnick, MD, Weill Cornell Medical College, New York, NY Speakers: Margaret A. Goodell, PhD, Baylor College of Medicine, Houston, TX Regulation of Hematopoietic Stem Cells by De Novo DNA Methyltransferases Lucy A. Godley, MD, PhD, University of Chicago, Chicago, IL 5-Hydroxymethylcytosine Control of Hematopoiesis Olivier A. Bernard, PhD, Institut Gustave-Roussy, Villejuif, France Epigenetic Alterations in Myeloid Malignancies Still want more on epigenetics? Meet the Symposium’s speakers for an informal Scientific Forum on Epigenetics in Hematopoiesis tomorrow from 11:15 a.m. to 12:15 p.m. Tickets can be purchased at the Ticketed Sessions counter in the Registration area of the convention center (tickets subject to availability). A boxed lunch will be provided. Also, if you missed it, check out the Section A article on this Symposium in today’s paper. broader minority recruitment initiative at ASH, which also includes the Minority Medical Student Award Program (MMSAP) and the ASH-Harold Amos Medical Faculty Development Program (ASHAMFDP) in partnership with the Robert Wood Johnson Foundation. The goal of the Minority Graduate Student Abstract Achievement Award is to attract minority PhD students to hematology and/or retain them in the field through the ASH annual meeting. At this meeting, students will have the oppor- tunity to hear the latest advances in hematology-related research and interact with ASH leadership, senior researchers, and minority physicians, scientists, and students. These awards are going to select graduate students to acknowledge their accomplishments in the field of hematology. Ujunwa Cynthia Okoye-Okafor Albert Einstein College of Medicine, Bronx, NY Abstract #2333 Adam Bush University of Southern California, Los Angeles, CA Abstract #3241 Colles Price University of Chicago Abstract #525 Jodi Murakami Beckman Research Institute, City of Hope Duarte, CA Abstract #2992 T CD30-directed therapy Important Safety Information Progressive multifocal leukoencephalopathy (PML): JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS™ (brentuximab vedotin). Concomitant use of ADCETRIS and bleomycin is contraindicated due to pulmonary toxicity. BOXED WARNING CT SCANS confirmed responses in relapsed patients Contraindication: Mx8000 Ex: CT080100137 Se: 8002/4 Im: 130/208 Ax: 1623.9 120.0 kV 280.0 mA 1.3 mm/-0.5:1 Tilt: 0.0 0.0s Lin:DCM/Lin:DCM/id:ID W:200 L25 Warnings and Precautions: • Peripheral neuropathy: ADCETRIS treatment causes a peripheral neuropathy that is predominantly sensory. Cases of peripheral motor neuropathy have also been reported. ADCETRIS-induced peripheral neuropathy is cumulative. Treating physicians should monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain or weakness and institute dose modifications accordingly. • Infusion reactions: Infusion-related reactions, including anaphylaxis, have occurred with ADCETRIS. Monitor patients during infusion. If an infusion reaction occurs, the infusion should be interrupted and appropriate medical management instituted. If anaphylaxis occurs, the infusion should be immediately and permanently discontinued and appropriate medical management instituted. • Neutropenia: Monitor complete blood counts prior to each dose of ADCETRIS and consider more frequent monitoring for patients with Grade 3 or 4 neutropenia. If Grade 3 or 4 neutropenia develops, manage by dose delays, reductions or discontinuation. Prolonged (≥1 week) severe neutropenia can occur with ADCETRIS. • Tumor lysis syndrome: Patients with rapidly proliferating tumor and high tumor burden are at risk of tumor lysis syndrome and these patients should be monitored closely and appropriate measures taken. R L 2860_sgn35_fa1_jog_ashnd.indd 1 10/15/12 5:28 PM 

Table of Contents for the Digital Edition of ASH News Daily 2012 - Saturday, December 8, 2012

ASH News Daily 2012 - Saturday, December 8, 2012

https://www.nxtbookmedia.com